Stock 603590 BEIJING KONRUNS PHARMACEUTICAL CO.,LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Beijing Konruns Pharmaceutical Co.,Ltd.

Equities

603590

CNE1000036K3

End-of-day quote Shanghai S.E.
Other stock markets
 18:00:00 2024-07-01 EDT 		5-day change 1st Jan Change
25.09 CNY -1.06% Intraday chart for Beijing Konruns Pharmaceutical Co.,Ltd. -1.03% -34.11%
04-25 Beijing Konruns Pharmaceutical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
04-08 Beijing Konruns Pharmaceutical Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Strengths

  • According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
  • The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
  • The company returns high margins, thereby supporting business profitability.
  • Analysts covering this company mostly recommend stock overweighting or purchase.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
  • Considering the small differences between the analysts' various estimates, the group's business visibility is good.

Weaknesses

  • For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
  • The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
  • Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.

Ratings chart - Surperformance

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
BEIJING KONRUNS PHARMACEUTICAL CO.,LTD. Stock Beijing Konruns Pharmaceutical Co.,Ltd.
-34.11% 555M -
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+55.55% 823B
C+
NOVO NORDISK A/S Stock Novo Nordisk A/S
+42.31% 641B
B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.83% 352B
C+
MERCK & CO., INC. Stock Merck & Co., Inc.
+17.15% 324B
B-
ABBVIE INC. Stock AbbVie Inc.
+7.09% 301B
C+
ASTRAZENECA PLC Stock AstraZeneca PLC
+14.02% 241B
B+
ROCHE HOLDING AG Stock Roche Holding AG
+1.64% 223B
A+
NOVARTIS AG Stock Novartis AG
+13.66% 218B
B-
AMGEN INC. Stock Amgen Inc.
+7.87% 167B
C+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
-

Valuation

P/E ratio
EV / Sales
-
Price to Book
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. 603590 Stock
  4. Ratings Beijing Konruns Pharmaceutical Co.,Ltd.